On the second edition of Gasoline Psychedelics Capital Conference, In sunny Miami, executives from four major ketamine therapy companies shared optimistic insights and guidance on the industry.

Revitalist L&Ws Kathryn Walker RVLWF, Jeffrey Becker (Bexson Biomedical), Cory Jones (healing cards) and Julia Mirer (Nushama) shared their views with a corporate M&A lawyer in a lively discussion about this non-classical psychedelic Benton Bodamer (Dickinson Wright) as moderator.

Ketamine, also known as your brain’s essential communicator

Walker, a 20-year-old nurse with 12,000 ketamine infusions to her credit, believes we need to close the chapter on mental health treatments of the last 50 years and start a new book.

Walker emphasized the fact that ketamine, the 50-year-old anesthetic that’s federally approved and a therapy covered by the VA, clearly works by blocking glutamate receptors and allowing glutamate, “our entire brain’s mother communicator,” to work.

She believes the medical community has become too specific when they should really keep knowledge about these brain drugs simple, and foresees the medical field that will eventually integrate the future system with the traditional one “because both need to be respected.”

Also read: EXCLUSIVE: In Reinventing Mental Health and Next-Generation Psychedelics, ‘Access and Clinical Data Are Key’

Understand where the real deal is

Becker, a longtime ketamine clinician, said it’s important to understand when businesses are built on quicksand, as they are after Ryan Haight Acts Waiver Extension During COVID Pandemic.

Following the recent case of telemedicine and its aftermath, he advises investors to study the legal landscape of this “heavily regulated industry” and the impact of ketamine therapy on medical practice.

So things like clinical care and services, profitable working time schedules and a clear understanding…